Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of CorMedix Inc (NASDAQ: CRMD) was $11.17 for the day, down -0.80% from the previous closing price of $11.26. In other words, the price has decreased by -$0.80 from its previous closing price. On the day, 2.47 million shares were traded. CRMD stock price reached its highest trading level at $11.58 during the session, while it also had its lowest trading level at $10.94.
Ratios:
Our analysis of CRMD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.83. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.94. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 30 ’25 when DUNTON ALAN W sold 20,000 shares for $13.00 per share. The transaction valued at 260,000 led to the insider holds 40,250 shares of the business.
Alan Dunton bought 20,000 shares of CRMD for $259,400 on Dec 30 ’25. On Dec 18 ’25, another insider, Todisco Joseph, who serves as the Chief Executive Officer of the company, sold 30,000 shares for $12.00 each. As a result, the insider received 360,000 and left with 509,496 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 880073664 and an Enterprise Value of 973277696. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.44, and their Forward P/E ratio for the next fiscal year is 4.47. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.11 while its Price-to-Book (P/B) ratio in mrq is 2.34. Its current Enterprise Value per Revenue stands at 4.542 whereas that against EBITDA is 8.995.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.39, which has changed by 0.0062556267 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 0.49%, while the 200-Day Moving Average is calculated to be -1.04%.
Shares Statistics:
CRMD traded an average of 2.76M shares per day over the past three months and 2299360 shares per day over the past ten days. A total of 78.35M shares are outstanding, with a floating share count of 69.26M. Insiders hold about 12.09% of the company’s shares, while institutions hold 56.59% stake in the company. Shares short for CRMD as of 1765756800 were 16875402 with a Short Ratio of 6.12, compared to 1763078400 on 17445325. Therefore, it implies a Short% of Shares Outstanding of 16875402 and a Short% of Float of 21.63.
Earnings Estimates
The dynamic stock of CorMedix Inc (CRMD) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.72, with high estimates of $0.72 and low estimates of $0.72.
Analysts are recommending an EPS of between $2.85 and $2.42 for the fiscal current year, implying an average EPS of $2.63. EPS for the following year is $2.5, with 2.0 analysts recommending between $2.53 and $2.47.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 7 analysts. It ranges from a high estimate of $135.16M to a low estimate of $120M. As of . The current estimate, CorMedix Inc’s year-ago sales were $31.21MFor the next quarter, 7 analysts are estimating revenue of $127.41M. There is a high estimate of $127.41M for the next quarter, whereas the lowest estimate is $127.41M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $318.25M, while the lowest revenue estimate was $303.09M, resulting in an average revenue estimate of $310.62M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $437.27M in the next fiscal year. The high estimate is $503M and the low estimate is $298.1M.
